ARCHIVES

Docetaxel, Oxaliplatin Active Against Esophageal Cancer

This article is from The Cancer Letter archive.

Vol. 29 No. 6 | June 30, 2006

Download PDF Visit The Full Archive

Related Articles

Dendreon Claims “Clear Hit” On Provenge, But Skeptics Await Data Presentation

April 17, 2009

Anil Potti Reprimanded by North Carolina Licensure Board

December 9, 2011

In Brief: Adamson’s Appointment Official As DCCP Director; NCI Holds Current Spending To 12 Percent Level

October 23, 1981

NCI Advisory Group, Other Cancer Meetings

January 30, 1976

Study Section Members Seek NIH Use Of Normalization, Sliding Scale

April 16, 1982

NCI Cuts Back Directed Research Funds, Encourages Investigator – Initiated Grants

February 23, 1996